Literature DB >> 27977512

Schisandrin B inhibits the proliferation and invasion of glioma cells by regulating the HOTAIR-micoRNA-125a-mTOR pathway.

Yan Jiang1, Qiuli Zhang, Jinsuo Bao, Chenghua Du, Jian Wang, Qiang Tong, Chang Liu.   

Abstract

Glioma is one of the most common malignant central nervous system tumors in humans. Schisandrin B (Sch B) has been confirmed to cause the proliferation and invasion of glioma cells. In the present study, the potential mechanism underlying the antitumor effect of Sch B on glioma cells was investigated. The glioma cell lines, U251 and U87, were exposed to Sch B, and the cell viability, apoptosis, migration, and invasion were determined using the MTT assay, flow cytometry, and transwell assay, respectively. Then, the effects of HOTAIR and miR-125a on tumor biology and the mammalian target of rapamycin (mTOR) protein expression in cell lines exposed to Sch B were investigated. The results showed that Sch B decreased HOTAIR expression and increased miR-125a-5p expression. HOTAIR overexpression decreased miR-125a expression and increased mTOR expression in cells with the treatment of Sch B. The miR-125a inhibitor reversed the effects of HOTAIR downregulation on cell proliferation and migration. On co-incubation with rapamycin, a specific mTOR inhibitor, the cell viability, migration, and invasion were decreased and cell apoptosis was increased in two cell lines exposed to Sch B after the treatment of pcDNA-HOTAIR. In conclusion, Sch B played an inhibitory role in the proliferation and invasion of glioma cells by regulating the HOTAIR-micoRNA-125a-mTOR pathway.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27977512     DOI: 10.1097/WNR.0000000000000717

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  8 in total

Review 1.  LncRNAs and CircRNAs in cancer.

Authors:  Xin Yin; Huiran Lin; Lei Lin; Lei Miao; Jing He; Zhenjian Zhuo
Journal:  MedComm (2020)       Date:  2022-05-12

2.  Schisandrin B down-regulated lncRNA BCYRN1 expression of airway smooth muscle cells by improving miR-150 expression to inhibit the proliferation and migration of ASMC in asthmatic rats.

Authors:  Xiao-Yu Zhang; Xue-Yi Tang; Li-Jun Ma; Ya-Li Guo; Xiao-Su Li; Li-Min Zhao; Cui-Jie Tian; Dong-Jun Cheng; Zhuo-Chang Chen; Luo-Xian Zhang
Journal:  Cell Prolif       Date:  2017-09-27       Impact factor: 6.831

Review 3.  A Comprehensive Review on Schisandrin B and Its Biological Properties.

Authors:  M I Nasser; Shuoji Zhu; Chen Chen; Mingyi Zhao; Huanlei Huang; Ping Zhu
Journal:  Oxid Med Cell Longev       Date:  2020-03-14       Impact factor: 6.543

Review 4.  Functional Interaction among lncRNA HOTAIR and MicroRNAs in Cancer and Other Human Diseases.

Authors:  Monica Cantile; Maurizio Di Bonito; Maura Tracey De Bellis; Gerardo Botti
Journal:  Cancers (Basel)       Date:  2021-02-02       Impact factor: 6.639

5.  Schisandrin B Induced ROS-Mediated Autophagy and Th1/Th2 Imbalance via Selenoproteins in Hepa1-6 Cells.

Authors:  Siran Tan; Zhi Zheng; Tianqi Liu; Xiaoyun Yao; Miao Yu; Yubin Ji
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 8.786

Review 6.  Two Worlds Colliding: The Interplay Between Natural Compounds and Non-Coding Transcripts in Cancer Therapy.

Authors:  Alexandru A Sabo; Maria Dudau; George L Constantin; Tudor C Pop; Christoph-M Geilfus; Alessio Naccarati; Mihnea P Dragomir
Journal:  Front Pharmacol       Date:  2021-07-06       Impact factor: 5.810

7.  The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma.

Authors:  Ana Xavier-Magalhães; Céline S Gonçalves; Anne Fogli; Tatiana Lourenço; Marta Pojo; Bruno Pereira; Miguel Rocha; Maria Celeste Lopes; Inês Crespo; Olinda Rebelo; Herminio Tão; João Lima; Ricardo Moreira; Afonso A Pinto; Chris Jones; Rui M Reis; Joseph F Costello; Philippe Arnaud; Nuno Sousa; Bruno M Costa
Journal:  Oncotarget       Date:  2018-02-28

Review 8.  Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review.

Authors:  Sara Momtazmanesh; Nima Rezaei
Journal:  Front Oncol       Date:  2021-07-12       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.